Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Clinical trial NCT05660954 · COMPLETED

Trial details

NCT number: NCT05660954
Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Differentiated Thyroid Cancer

Start date: 2023-05-25
Primary completion: 2025-11-30
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.